Who is sponsoring NCT04189614?

NCT04189614 is sponsored by AbbVie.

What condition does NCT04189614 study?

NCT04189614 studies Cancer, Non-small Cell Lung Cancer (NSCLC).

What drugs are being tested in NCT04189614?

Interventions: Cofetuzumab Pelidotin.

What is the status of NCT04189614?

NCT04189614 is currently ACTIVE_NOT_RECRUITING.

Last reviewed 2026-03-20 · How we verify

A Phase 1b Efficacy and Safety Study of Cofetuzumab Pelidotin (ABBV-647, a PTK7-Targeting Antibody Drug Conjugate) in Subjects With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer

NCT04189614 Phase 1 ACTIVE_NOT_RECRUITING

This study is being done to determine the efficacy and safety of cofetuzumab pelidotin in the PTK7-expressing, recurrent non-small cell lung cancer (NSCLC) population.

Details

Lead sponsor	AbbVie
Phase	Phase 1
Status	ACTIVE_NOT_RECRUITING
Enrolment	65
Start date	2020-02-13
Completion	2026-05

Conditions

Cancer
Non-small Cell Lung Cancer (NSCLC)

Interventions

Cofetuzumab Pelidotin

Primary outcomes

Objective Response Rate (ORR) — Up to approximately 3 years
ORR assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria and defined as the percentage of participants with confirmed complete response (CR) or confirmed partial response (PR).

Countries

United States, Israel, Japan, South Korea, Spain, Taiwan